Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin versus Tolvaptan in adults with Autosomal Dominant Polycystic Kidney Disease
2024-517864-49-01Phase 3Authorised
- Sponsor
- University of Bari Aldo Moro
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in autosomal dominant polycystic kidney disease (ADPKD) comparing Metformin with Tolvaptan (Jinarc) (2 arms). Primary endpoint: Annualized slope of eGFR (CKD-EPI). Planned start Jan 2025; status: authorised.
02
Drugs
metformintolvaptan
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on 2024-517864-49-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517864-49-01.